Anti-LAG-3 blockade monotherapy didn't demonstrate significant anti-tumor effects, and dual blockade of PD-1 and LAG-3 showed strong synergistic anti-tumor immune responses in preclinical studies46–48. Here, PDCD1 is linked to neoplasm.